Alnylam Pharmaceuticals (NASDAQ:ALNY) is preparing to release its quarterly earnings on Thursday, 2026-02-12. Here’s a brief overview of what investors should keep in mind before the announcement.
Analysts expect Alnylam Pharmaceuticals to report an earnings per share (EPS) of $1.20.
The announcement from Alnylam Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It’s worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
During the last quarter, the company reported an EPS beat by $1.67, leading to a 1.44% increase in the share price on the subsequent day.
Here’s a look at Alnylam Pharmaceuticals’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.23 | -0.16 | -1.03 | -0.14 |
| EPS Actual | 2.90 | 0.32 | -0.01 | 0.06 |
| Price Change % | 1.00 | 2.00 | 2.00 | -3.00 |
Market Performance of Alnylam Pharmaceuticals’s Stock
Shares of Alnylam Pharmaceuticals were trading at $322.98 as of February 10. Over the last 52-week period, shares are up 21.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Insights on Alnylam Pharmaceuticals
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Alnylam Pharmaceuticals.
The consensus rating for Alnylam Pharmaceuticals is Buy, derived from 11 analyst ratings. An average one-year price target of $472.27 implies a potential 46.22% upside.
Comparing Ratings with Competitors
This comparison …